Kala Bio KALA
NASDAQ KALA
$0.18 +0.02 (+13.62%)
As of: Nov 9, 2026 · 1:50 PM EST

Kala Bio (KALA) Purchase of Investments (2020 - 2026)

Updated

Analysis

Kala Bio (KALA) Purchase of Investments (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Purchased (Qtr)
1 Eli Lilly 1,258.81 Bn 1,232.43 Bn 20.46 Bn 258.00 Mn
2 Johnson & Johnson 680.59 Bn 600.45 Bn 17.30 Bn 919.00 Mn
3 AbbVie 519.40 Bn 487.41 Bn 13.12 Bn 300.00 Mn
4 Merck 366.82 Bn 329.76 Bn 13.19 Bn -
5 Novartis Ag 317.32 Bn 290.56 Bn - -
6 Astrazeneca 294.21 Bn 268.10 Bn 13.26 Bn -
7 Amgen 251.17 Bn 202.82 Bn 7.58 Bn -
8 Gilead Sciences 210.27 Bn 185.38 Bn 6.73 Bn 1.00 Mn
9 Pfizer 168.21 Bn 115.56 Bn 12.56 Bn 4.40 Bn
10 Kala Bio 2.70 Mn -41.94 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 7.00 Mn
Mar 31, 2022 4.99 Mn
Sep 30, 2020 57.06 Mn
API Access

Kala Bio Purchase of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=purchase-of-investments&ticker=KALA&period=max&api_key=YOUR_API_KEY